Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma
Explore a simultaneous population PK/PD model characterizing the dynamic relationships between belantamab mafodotin, sBCMA, and…
Certara2026 年 10 月 5 日
Model-Informed Strategies for ADC Development
Explore how model informed drug development can help ADC developers optimize dosing, reduce uncertainty, strengthen…
Danielle Pillsbury2026 年 9 月 22 日
Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy
Pharmacometric modeling of givinostat in pediatric DMD supported a simplified 4-band weight-based dosing regimen without…
Certara2026 年 9 月 14 日
A glimpse into the future of model-informed drug discovery and development
Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…
Certara2026 年 8 月 28 日
Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology
Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…
Certara2026 年 8 月 28 日
A model-informed approach to radioligand therapy dosing under Project Optimus
Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…
Hunter Stephens, PhD2026 年 8 月 13 日
From Dosimetry to Dose Decisions: How Clinical Pharmacology and Model-Informed Approaches Are Shaping TRT Development
Learn how dosimetry, clinical pharmacology, pharmacometrics, QSP, and regulatory strategy support dose optimization for therapeutic…
Hunter Stephens, PhD2026 年 7 月 17 日
Dosimetry for radiopharmaceutical therapy: From measurement to dose justification
Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…
Hunter Stephens, PhD2026 年 7 月 7 日
